Head-to-head evidence
ABBV-RGX-314 vs KSI-301
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Age-Related Macular Degeneration
Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline
ABBV-RGX-314
Developed by AbbVie
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT04704921 (registry estimate)
KSI-301
Developed by Kodiak Sciences Inc.
NCT04964089 · Phase 3 · completed
This was a randomized, triple-masked, active-controlled trial with 276 participants receiving KSI-301 and 281 receiving aflibercept. The hard clinical primary endpoint, change in best-corrected visual acuity, met the prespecified non-inferiority criterion: the adjusted difference was -2.1 ETDRS letters (95% CI -3.88 to -0.29; p=0.0083).
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ABBV-RGX-314's landscape · KSI-301's landscape